The performance of turbo codes can often be improved by improving the weight spectra of such codes. Methods of producing the weight spectra of turbo codes have been investigated and many improvements were made to refine the techniques. A much faster method of weight spectrum evaluation has been developed that allows calculation of weight spectra within a few minutes on a typical desktop PC. Simulation results show that new high performance turbo codes are produced by the optimisation methods presented. The two further important areas of concern are the code itself and the decoding. Improvements of the code are accomplished through optimisation of the interleaver and choice of constituent coders. Optimisation of interleaves can also be accomplished automatically using the algorithms described in this work. The addition of a CRC as an outer code proved to offer a vast improvement on the overall code performance. This was achieved without any code rate loss as the turbo code is punctured to make way for the CRC remainder. The results show a gain of 0.4dB compared to the non-CRC (1014,676) turbo code. Another improvement to the decoding performance was achieved through a combination of MAP decoding and Ordered Reliability decoding. The simulations show a performance of just 0.2dB from the Shannon limit. The same code without ordered reliability decoding has a performance curve which is 0.6dB from the Shannon limit. In situations where the MAP decoder fails to converge ordered reliability decoding succeeds in producing a codeword much closer to the received vector, often the correct codeword. The ordered reliability decoding adds to the computational complexity but lends itself to FPGA implementation.

As Pseudomonas aeruginosa adapts to the Cystic Fibrosis (CF) and chronic obstructive pulmonary disease (COPD) lung environments, mucoid strains often appear as a result of alginate overproduction. Such mucoid conversion is associated with the establishment of a chronic pulmonary infection. Alginate confers resistance to phagocytosis and has other pathogenic properties. The regulation of alginate production is complex and involves an alternate sigma factor, anti-sigmas and several DNA-binding transcriptional regulators. Here we examined the possibility that the catabolic repression control (Crc) protein repressor may affect alginate gene expression. A putative Crc binding site was observed adjacent to the ribosome binding site of algD, the first gene in the 12-gene alginate biosynthetic operon. We hypothesized that Crc binding here would act as a repressor of algD expression. Taking a genetic approach, Gateway technology was used to construct crc::GmR (nonpolar) mutants of P. aeruginosa strain PAO1 and its mucoid (mucA) mutant derivative, PDO300. The crc mutation had the expected phenotypes with respect to pyocyanin production, biofilm formation and diauxic growth. When a PalgD-lacZ (translational) fusion was tested, the crc mutant showed increased algD expression as predicted for a mRNA-binding repressor. Another Ptrc-algD-lacZ (translational) construct, but missing the upstream promoter (PalgD) elements, also showed increased activity in crc mutants as predicted if Crc was acting directly as a repressor of algD transcriptional / translational expression. However, this was not consistent with the production of alginate. The crc mutant of mucoid PDO300 showed lower levels of alginate production than its parent strain. Under conditions were the algD operon was induced by ammonium metavanadate in the growth medium to produce alginate, the crc mutation again resulted in a lower level of alginate production than wild-type, which was again inconsistent with the algD-lacZ expression data. This suggests that crc mutation, which has global effects on carbon flow in the cell, could be affecting metabolic pathways that feed precursors into the alginate biosynthetic pathway. Future directions for this research are discussed.

Introduction: Van Gogh-Like 2 (VANGL2) is a scaffolding planar cell polarity protein involved in non-canonical Wnt signalling. It has been shown to have crucial roles in regulating epithelial development and homeostasis. Moreover, VANGL2 has been implicated in human cancers, with increased expression and copy number amplification seen in several cancer contexts. Many related components within this pathway have also been linked to cancer development, with VANGL2 expression known to regulate factors involved in cell migration and extracellular matrix (ECM) remodelling in cell lines. These cellular processes tend to be erroneously activated in cancer. VANGL2 is known to inhibit the classical driver pathway of colorectal cancer (CRC), canonical, or β- catenin dependant, Wnt signalling, in CRC cell lines. The aim of this thesis is to determine the expression of VANGL2 in CRC, and to investigate how VANGL2 may act to regulate intestinal homeostasis and disease. Methods: Transcriptional verification of VANGL2 expression in the mouse intestine was carried out by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR), and transcripts localised within the murine colon using RNA-In Situ Hybridisation (RNAISH). Expression and localisation of the VANGL2 protein and related non-canonical Wnt signalling components was confirmed using immuno-histochemistry (IHC). Furthermore, using a combination of human Tissue Micro-Array (TMA), transcriptional data and genomic data, we determined an association between VANGL2 on tumour grade and disease-free survival. To functionally validate the effects of VANGL2 on colorectal biology, we used a model in which VANGL2 is selectively deleted from the colonic epithelium using Villin-CreERT Vangl2flox mouse lines. Using a combination of molecular biology methods, we identified the ECM as differentially regulated following VANGL2 modulation. To test the role of VANGL2 in colorectal cancer, we used a murine colorectal cancer model in which adenomatous polyposis coli (APC) is deleted from colonic epithelium resulting in the formation of cancer concurrently with deletion of Vangl2. We evaluated survival of these mice as well as tumour number and size. Tumour tissue was analysed using IHC, qRT-PCR and 3-Dimensional organoid culture. Results: Within this thesis I have illustrated that the murine colonic epithelium expresses Vangl2, and other components known to interact with VANGL2 including Vangl1, Wnt5A, and Protein Tyrosine Kinase 7 (Ptk7). I have also shown that VANGL2 is expressed within the human colonic epithelium. I go on to show that 9.2% of human CRC possesses VANGL2 transcriptional alterations which correlates with a worsened disease-free survival (DFS) rate among patients. Using IHC, I also show that higher grade CRC is associated with increased VANGL2 expression. In our murine cancer model, mice with single or dual-copy loss of VANGL2 were found to have a reduced number of colonic tumours, while maintaining similar tumour size. Investigations to identify how VANGL2 may have control of tumour initiation were carried out focussing on the ECM. I found that, contrary to what I have discovered in the healthy murine colon, tumours from VANGL2-deficient mice had increased transcription of the ECM markers Secreted protein acidic and rich in cysteine (Sparc) and Decorin (Dcn), as well as increased expression of the ECM regulators Matrix Metallopeptidase 9 (Mmp9) and Tissue Inhibitor of Metalloproteinases 1 (Timp1). Changes in the ECM was also seen at the protein level, with increases in staining for the ECM components Col1 (Collagen, type I), and Laminin in VANGL2-deficient tissue. The ECM modulator Connective Tissue Growth Factor (Ctgf), is implicated in multiple cancers including CRC and is increased within VANGL2-deficient tumours at both the transcript and protein level, implicating Ctgf in increasing the ECM of these tumours.

Hyperactive Wnt signaling is the seminal event in colorectal cancer (CRC) pathogenesis, where β-catenin serves as a key Wnt mediator enhancing CRC cell proliferation and survival. c-Cbl is a unique E3 ligase, which degrades both mutant and active (tumorigenic) β-catenin. c-Cbl phosphorylation at tyrosine 731 (Y731) regulates its binding and down regulation of β-catenin specifically in the presence of Wnt ligand (Wnt-on state). Since aberrant Wnt signaling activation is found in almost all cases of human CRC, it would be critical to understand the influence of c-Cbl phosphorylation on CRC cell survival. We hypothesized that c-Cbl phosphorylation regulates CRC cell survival in a Wnt dependent manner, a state that is mediated through mutations in β-catenin or adenomatosis polyposis coli (APC). Cbl phosphorylation was examined in a panel of Wnt-off cells with wild-type β-catenin and APC CRC cell line (RKO cell line) and Wnt-on cell lines with mutant APC (Wnt-on- DLD1, HCT15 cell line) or mutant β-catenin (HCT116) using phospho-specific antibodies to c-Cbl tyrosine residues at 700 (Y700), 731 and 774 (Y774) positions. Biological significance of specific phosphorylation sites was evaluated with phospho-inactive mutants of c-Cbl (Y700F, Y731F and Y774F) using both the MTT cell proliferation assay and the non-adherent colony formation assay. Potential meditators of c-Cbl were examined using immunoblotting. Here we show that c-Cbl was phosphorylated at all three major phosphorylation sites (Y700, Y731 and Y774) in both Wnt-off and Wnt-on CRC cell lines. However, the amount of phosphorylation was reduced in Wnt-on CRC cell lines (DLD1, HCT116 and HCT15) compared to Wnt-off (RKO) cell line. Wild-type c-Cbl significantly enhanced survival in RKO cell lines and reduced survivability in DLD1 cell lines. In contrast to the effect of wild-type c-Cbl, Y731F increased CRC cell survival and non-adherent colony forming units. Our preliminary data suggests that c-Cbl Y731 mutation regulates CRC survival through β-catenin. c-Cbl is heavily phosphorylated in CRC cell lines, where wild-type c-Cbl significantly inhibits cell survival in Wnt-on and enhances cell survival in Wnt-off CRC cell lines. Furthermore, our data indicates that Y731 influences CRC survival and colony formation only in Wnt-on cell lines. Though further validation is required, this dichotomy in the effect of c-Cbl phosphorylation on CRC survival being mediated by Wnt status can be further explored as a potentially novel therapeutic target in mutant CRC tumors, which represent more than 90% of CRC cases in humans.

According to the Swedish curriculum every child has the right to feel safe in school. Also according to CRC (committee on the rights of the child) the child has the right to be respected and provided for his or hers basic needs. The teachers must also develop equality for the children and they should also counteract insults. But even though we have these laws and rules some children feel unsafe at school. Every day 60 000 children are being bullied at schools in Sweden. This is a huge problem that needs to be addressed. The aim of this thesis is to investigate teachers in different schools and their strategies to handle bullying. The method is qualitative interviews of teachers. The result indicates that the teachers do see things differently from each other, and that can lead to complications later on. The complications do not only regard the student in that way that they are being treated differently in different schools. It can also affect the teachers in that way that they does not see the harm in what some kids do that other would call bullying.

Background: Conventional chemotherapeutics target bulk tumour cells and generally leave cancer stem cell (CSC) populations unaffected. Recent literature characterized the presence and the role of CSC in several types of solid tumors, including colorectal cancer. Colorectal CSCs (CCSCs) display enhanced WNT/β-catenin pathway activity, sustaining self-renewal and tumor-initiating capacity. Thus, CCSCs are crucial for tumour recurrence and metastasis. As one of the main contributors to sustained self-renewal activity in CCSCs, enhanced formation of β-catenin/CBP complex is fostering transactivation of canonical WNT target genes such as c-myc. However, maintenance of healthy intestinal stem cells also dependents on the canonical WNT pathway. Thus, selective targeting CCSCs while sparring normal intestinal cells is still a significant challenge. Interestingly, Sam68 is a key mediator of the interaction between β-catenin and CBP. It has been reported as a “druggable” target to selectively disrupt β-catenin/CBP in CSCs. Indeed, CWP232228 successfully targets CSCs in AML by facilitating Sam68/CBP complex formation, and consequently lowering the abundance of β-catenin/CBP complexes. CWP232228 was clinically tested on multiple human cancers. Unfortunately, such clinical trials were halted due to unknown causes, and limited information was released on clinical safety and benefits. Consequently, developing more potent pharmacological modulators of Sam68/CBP complex formation is still highly relevant to eradicate CCSCs. Here we describe the discovery and characterization of a new CWP analog, known as YB-0158, which displays enhanced potency and neoplastic selectivity against CCSC. Methods and Results: Following the confirmation that ICG/CWP class of compounds bind to Sam68 in CSCs, I used in silico docking methods to screen for CWP analogs having high predicted affinity for Sam68 Cterminal proline-rich domain. Using high content imaging techniques, I confirmed our top candidate (YB-0158) as more potent vs. CWP parent molecule to compromise cell growth, to induce loss of pluripotency, and to increase Sam68 nuclear localization in a surrogate model of human CSCs. YB-0158 also displayed enhanced selective toxicity in colorectal cancer models vs. normal intestinal epithelium progenitor cells. Moreover, I confirmed that YB-0158 exert negative impact on cancer cell growth by inducing apoptosis and reducing proliferation. Lentiviral-based knockdowns explicitly displayed decrease in drug effectivity in the absence of Sam68, reinforcing the essential role of Sam68 mediating ICG-001/CWP response in CSCs. I demonstrated that Sam68 expression is enriched in tumor-initiating cell fractions derived from primary colorectal tumor tissues vs. bulk heterogeneous tumor organoids. Therefore, YB-0158 showed striking efficacy at supressing tumor-initiation activity in a patient-based serial organoid formation assay. Finally, YB-0158 eradicated CSCs activity in vivo as demonstrated by a syngeneic mouse-to-mouse serial transplantation assay. Conclusion: Overall, YB-0158 is a novel analog of CWP232228 with superior potency to target CCSCs activity through facilitation of Sam68 nuclear localization, thus reducing the interaction frequency between CBP and β-catenin.

No description available.

Considéré comme un cancer de l'âge mûr, l'incidence du cancer colorectal ne cesse d'augmenter avec l'allongement de la vie. Dans la majorité des cas, le cancer colique est associé à une mutation du gène suppresseur de tumeur Apc, contrôlant l’activation de la signalisation Wnt/β-caténine. Afin, d'identifier de nouveaux acteurs de la tumorigenèse colique, notre laboratoire a développé des modèles murins de mutation du gène Apc qui ont pour avantage de mimer la pathologie humaine (Colnot et al, 2004 ; Andreu et al, 2005). La création de ces modèles a permis à l’équipe de démontrer i) qu’une activation physiologique de cette voie contrôle la prolifération des cellules souches et des progéniteurs ainsi que leur différenciation et ii) qu’une activation aigüe est suffisante pour déclencher l’initiation tumorale intestinale (Andreu et al, 2005; Andreu et al, 2008). Les travaux antérieurs à mon arrivée ont permis d’identifier différents évènements moléculaires et cellulaires induits en cascade suite à l’activation pathologique de la voie Wnt/β-caténine. Parmi ceux-ci, une induction transcriptionnelle de gènes impliqués dans l'autophagie a été mise en évidence. Ce processus d'auto-cannibalisme cellulaire est associé à de nombreuses pathologies telles que les maladies neurodégénératives ou infectieuses. Cependant, le rôle de l'autophagie dans le cancer reste ambivalent et son implication dans le cancer colique demeure inconnue.Dans ce contexte, mon travail de doctorat a consisté à répondre aux questions suivantes :L’induction transcriptionnelle de gène Atg s’accompagne-t-elle d’une activation du processus d’autophagie à tous les stades de la progression tumorale intestinale murine et humaine?Des études de transcriptomique à haut débit nous ont permis d’identifier une induction transcriptionnelle de gènes clés du processus d’autophagie tels qu’Atg7. Cependant, l’activation fonctionnelle de l’autophagie n’est pas toujours associée à une augmentation de la transcription des acteurs de ce processus. Nous nous sommes donc intéressés aux marqueurs couramment décris dans la littérature et permettant d’établir l’état d’activation du flux autophagique. Ainsi, nous avons étudié le niveau d’expression de ces marqueurs par des expériences de western-blot et d’immuno-marquages sur des échantillons tumoraux humains et murins à différents stades de la progression du CRC. L’inhibition de l’autophagie impacte-t-elle la carcinogénèse colorectale?Dans ce contexte, nous avons généré un modèle murin de délétion conditionnelle et simultanée d'un allèle du gène Apc et des deux allèles du gène Atg7 (gène clé de l'autophagie) spécifiquement dans les cellules épithéliales intestinales. Afin de suivre l'apparition et l'évolution des tumeurs au cours du temps, nous avons mis au point une nouvelle méthode non-invasive de reconstruction tridimensionnelle de côlons de souris, issue d'imagerie échographique à haute résolution. Dans le but de caractériser l’impact de l’inhibition de l’autophagie, les modifications propres à la cellule déficiente en autophagie ont été explorées, notamment le statut énergétique ainsi que les changements dans l’environnement immunitaire et microbien de l’épithélium intestinal. Finalement, l’inhibition génétique de l’autophagie dans notre modèle murin, prédisposé au développement de tumeurs intestinales, nous a permis de caractériser l’implication de l’autophagie dans la carcinogénèse colique, ainsi que les mécanismes moléculaires et cellulaires liant l’auto-cannibalisme cellulaire à la pathologie tumorale. / Colorectal cancer is one of the major causes of cancer-related deaths. We took advantage of Apc mutant mice that mimic the adenomatous polyps that affect humans with an inactivated Apc gene, to gain insight into the critical events that affect the development of colorectal cancer. We show that autophagy, a catabolic pathway involved in the degradation of intracellular proteins and organelles, is activated in intestinal murine and human cancer and its inhibition has a crucial role in controlling tumorigenesis. We report that the in vivo conditional deletion of the essential autophagy gene Atg7 in intestinal epithelial cells inhibits the formation of pre-cancerous lesions resulting from Apc loss by enhancing immunosurveillance. The antibody-mediated depletion of CD8+ T cells demonstrated a critical role for CD8+ T cells in antitumoral responses resulting from the inhibition of autophagy. We used a broad-spectrum antibiotics treatment to show that the expansion of IFN-producing CD8+ T cells following the deletion of Atg7 is dependent on the intestinal microbiota and is associated with Paneth and goblet cell defects. In addition, the inhibition of autophagy affected tumor cell growth and restrained cancer growth for extended time periods. We demonstrate that the inhibition of autophagy in Apc tumor cells results in a stress response accompanied by metabolic defects, characterized by AMPK activation and p53 cell cycle arrest. This study suggests that autophagy inhibitors may suppress tumorigenesis in patients at high risk of developing colorectal cancer.

Colorectal cancer (CRC), which includes cancer of the large bowel and rectum is the third most common cancer in men and the second in women and there is a poorer survival rate in less developed regions of the world such as West Africa mainly due to the ‘out of reach’ costs of chemotherapy. Evidence suggests that aspirin, a non-steroidal anti-inflammatory drug (NSAID) has the potential to decrease incidence of, or mortality from, a number of cancers including CRC through several mechanisms of action. However, this evidence is dampened by aspirin’s gastrointestinal (GI) toxicity, which have been found to be mostly age-dependent. The search for potential aspirin-related compounds with the same or better cytotoxic effects against cancer cells accompanied by a safer toxicity profile has been ongoing over the years and led to us to synthesise a number of novel aspirin analogues. One of the mechanisms of action suggested for the anticancer property of aspirin is the COX-dependent pathway. In this thesis SW480 cell line, a CRC cell line that is COX-2 negative and mismatch repair (MMR) proficient was used to study the possible COX-independent mechanism of action for aspirin, its analogues and diflunisal at 0.5 mM. Diflunisal was included in this study because it is also a salicylate with reports of having cytotoxic effects. OE33 and FLO1 oesophageal cancer cells were also employed in the epidermal growth factor receptor (EGFR) and synergy experiments to show effects were not just specific to SW480 cells alone. These aspirin analogues were synthesised, identified using nuclear magnetic resonance (NMR) and infra-red (IR) spectroscopy, and tested for purity using thin layer chromatography (TLC) and melting point. The findings of this study suggest that these compounds breakdown into salicylates and perturb epidermal growth factor (EGF) internalization with PN517 (fumaryldiaspirin) and PN590 (ortho-thioaspirin) also driving EGF co-localization with early-endosome antigen-1 (EEA1). The perturbation of the internalization of EGF by aspirin and PN517 was also observed by a time-lapse assay using live confocal imaging. These compounds also had specific effects on different tyrosine phosphorylation sites of the EGFR, with none but PN590 inhibiting 4 phosphorylation at Y1068, and all but PN502 (ortho-aspirin), PN548 (meta-aspirin) and PN549 (para-aspirin) inhibiting phosphorylation at Y1045 and Y1173. Given that the EGF internalization assay involved the cells being treated with compounds for 2 h, cells were also treated for this same time period and probed with pEGFR 1045, which resulted in the compounds having no significant effect on phosphorylation at that site which is responsible for the ubiquitination of the EGFR. Most of these compounds were apoptotic with some showing a combination of apoptosis and necrosis. Aspirin and its isomers drove apoptotic cell death in SW480 cells via the BCL2-BAX pathway while the thioaspirins appear to follow the p21 pathway by decreasing the expression of the protein. In addition, it was shown that PN502 (aspirin), PN517 and PN590 had synergistic effects when used in combination with oxaliplatin at ED50, ED75 and ED90 in SW480 CRC cells. The cytotoxicity of these compounds individually or in combination was determined using MTT assay followed by the use of the CompuSyn and CalcuSyn software to calculate combination index (CI), which indicated whether a drug combination was synergistic, antagonistic or additive. PN517 and PN524 were synergistic when used in combination with cisplatin in OE33 oesophageal cancer cells. Effect of these compounds on the EGFR indicates a delay or disruption of the signalling pathway involved in the proliferation of cancer cells, thus, translating into protection against tumour formation or progression while the synergistic effects of these compounds when used in combination with platinum compounds can provide patients with less toxic chemotherapeutic regimen especially in patients with CRC tumours that harbour mutant TP53 gene and normally resistant to oxaliplatin. It is therefore proposed that the perturbation of EGF internalization is a novel mechanism of action for aspirin and its analogues in cancer therapy. These positive findings shed light on the understanding of the possible mechanism of action for aspirins and gives hope for a more affordable, less toxic therapy for the prevention, treatment and management of cancer.

Le diabète est une dérégulation systémique chronique caractérisée par des perturbations métaboliques permanentes à l’origine de nombreuses complications, y compris le cancer. Le diabète augmente le risque du cancer colorectal (CRC) de 1,2 à 1,5 fois. Cependant, les voies moléculaires et cellulaires en jeu ne sont pas assez élucidées. Nos résultats témoignent d’une dérégulation de la voie AMPK/mTORC1 dans le diabète et le CRC avec une surexpression de la NADPH oxydase Nox4, augmentant ainsi la production de ROS. Ceci provoque un stress oxydatif qui s’élève en cas de diabète et contribue à la progression du CRC. De plus, nos résultats montrent que ce stress induit une altération de la voie de signalisation AMPK/mTORC1, aboutissant à une agressivité accrue du comportement des cellules cancéreuses du côlon et de la formation de polypes. Notre projet permet, d’une part, d’identifier de nouveaux mécanismes moléculaires impliqués dans la progression du CRC induite par le diabète et d’autre part, de développer des stratégies thérapeutiques efficaces pour inverser la progression du CRC chez les patients diabétiques. / Diabetes is a chronic systemic malfunction characterized by persistent metabolic disturbances that culminate in a high rate of complications to which cancer was recently annexed. In fact, diabetes inflates colorectal cancer (CRC) risk by 1.2-1.5 folds. However, the cellular and molecular pathways involved are not well understood. Our results show that AMPK/mTORC1 pathway is deregulated in both diabetes and CRC. This was paralleled by an elevation in the expression of the NADPH oxidase Nox4 leading to an increase in ROS production. Furthermore, our results show that oxidative stress, secondary to alteration in the level and activity of Nox4 is augmented in diabetes and contributes to the progression of CRC. The resulting oxidative stress further led to an alteration in the signaling of the AMPK/mTORC1 pathways culminating in an exacerbated aggressiveness in cancer cell behavior and colon polyp formation. Our project allows the identification of novel molecular mechanisms involved in diabetes-induced CRC progression and development of effective therapeutic strategies to reverse the progression of CRC in diabetic patients.